Charles River Laboratories International Inc [CRL] stock is trading at $152.75, up 2.56%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRL shares have lost -8.80% over the last week, with a monthly amount drifted -3.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Charles River Laboratories International Inc [NYSE: CRL] stock has seen the most recent analyst activity on July 09, 2025, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $200 for it. Previously, Redburn Atlantic upgraded its rating to Buy on May 23, 2025, and kept the price target unchanged to $182. On May 14, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $179 on the stock. Evercore ISI upgraded its rating to a Outperform but stick to its price target of $170 on May 08, 2025. Goldman downgraded its rating to a Neutral and reduced its price target to $170 on March 21, 2025. Citigroup upgraded its rating to Neutral for this stock on March 04, 2025, and upped its price target to $175. In a note dated March 03, 2025, Redburn Atlantic upgraded an Neutral rating on this stock but restated the target price of $188.
Charles River Laboratories International Inc [CRL] stock has fluctuated between $91.86 and $230.02 over the past year. Currently, Wall Street analysts expect the stock to reach $303.6 within the next 12 months. Charles River Laboratories International Inc [NYSE: CRL] shares were valued at $152.75 at the most recent close of the market. An investor can expect a potential return of 98.76% based on the average CRL price forecast.
Analyzing the CRL fundamentals
Charles River Laboratories International Inc [NYSE:CRL] reported sales of 4.03B for the trailing twelve months, which represents a growth of 0.59%. Gross Profit Margin for this corporation currently stands at 0.24% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at -0.0%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.02 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 149.85 points at the first support level, and at 146.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 154.83, and for the 2nd resistance point, it is at 156.91.
Ratios To Look Out For
For context, Charles River Laboratories International Inc’s Current Ratio is 1.36. Also, the Quick Ratio is 1.10, while the Cash Ratio stands at 0.17. Considering the valuation of this stock, the price to sales ratio is 1.87, the price to book ratio is 2.24.
Transactions by insiders
Recent insider trading involved LaPlume Joseph W, EVP, Corp Strategy & Develop, that happened on Aug 07 ’25 when 400.0 shares were sold. Officer, Joseph LaPlume completed a deal on Aug 07 ’25 to buy 400.0 shares. Meanwhile, Former Director WALLMAN RICHARD F bought 8500.0 shares on Jul 21 ’25.
